Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 28;69(9):1677–1690. doi: 10.1136/gutjnl-2019-319091

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

TgfB2-silencing by AONs reduced biliary damage and ductular reactions (DR). Immunohistochemical staining of (A) CK19, (B) Sox9, (C) and panCK, as well as (D) immunofluorescence-based detection of Epcam as a markers of DR and (E) qPCR of Muc1 as a marker of biliary damage revealed significant downregulation in AON-treated MDR2-KO mice. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001; scale bars indicate 50 µm for CK19, and 100 µm for Sox9, panCK and Epcam. AON, antisense oligonucleotides; MDR2-KO, multidrug resistance gene 2 knockout; Muc, Mucin; TGFB, transforming growth factor beta.